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1. Objectives of This Special Issue
Chronic liver diseases (CLD) are serious health-threatening
problems worldwide. In particular, it is a significant health-
care burden in SoutheastAsian countrieswhere viral hepatitis
is common. Regardless how the diseases are initiated, without
proper intervention, CLD may gradually progress towards
end-stage liver disease (ESLD), for which liver transplanta-
tion remains the only solution. Although this progression
may be slow and gradual, there is no evidence showing that it
could be reversed when cirrhosis has developed. Preventive
intervention that may impede the progression of CLD is
clinically favourable. Management of CLD depends on the
etiology, and supporting treatment and hepatoprotective
medicines are often provided. However, drug resistance and
various adverse effects can lead to failure of treatment.
Many countries have their own traditional medicines and
herbal medicines are the main therapeutic materials in most
traditional medicines. In the past decades, herbal medicines
have been widely used to treat liver diseases. The pros and
cons of herbal medicines for treatment of liver diseases are
intensively debated in recent years. The main goal of this
special issue is to showcase the latest research in this research
area to promote academic exchanges and disseminate the
state of the art.
2. Analysis of This Special Issue
This special issue covers cutting-edge research topics on
herbal medicines in hepatology, including original research
articles and current reviews in the following categories:
(i) Basic, translational, and clinical studies of herbal
medicines for preventing and treating liver diseases
and their complications.
(ii) Liver injury induced by herbal medicines and herb-
drug interaction.
(iii) Systematic reviews on studies of herbal compounds,
herbs, and herbal formulae for liver diseases.
After a rigorous peer-review process, the special issue
accepted nine manuscripts, including six original research
papers and three review papers, out of 30 submissions. The
accepted papers were financially supported by various fund-
ing schemes from different countries and regions including
Mainland China, Hong Kong, Canada, Egypt, and South
Korea.
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Original research articles in this special issue focus on
either herbal medicine compounds or composite herbal
extracts, reporting novel pharmacological activities and
applying new research methodology. The study from Gha-
reeb and colleagues investigated the therapeutic potential of
berberine against neurotoxicity-related Alzheimer’s disease,
a secondary complication of nonalcoholic steatohepatitis
(NASH) in a rodent model of NASH, and demonstrated that
berberine had anti-inflammatory and antioxidative activities
and selectively suppressed AChE and HMG-CoA. Interest-
ingly, study from Wang and colleagues also reported that
berberine regulated viability and activation of hepatic stellate
cells and prevented fibrogenesis in in vitro and in vivo liver
disease models. The two papers highlighted the potential of
berberine in the treatment of CLD and related complications.
Kim and colleagues reported a herbal formula used for
antifibrotic treatment in Korean Medicine. This formula,
known as CGXII, effectively prevented dimethylnitrosamine-
induced hepatic fibrosis. Chen and colleagues reported the
preventive effect of Buzui recipe, a Chinese Medicine recipe,
on alcoholic intoxication in mice and the effects may be
associated with the antioxidative activity of the recipe.
Wang and colleagues offered new insights into the research
methodologies on pharmacological activities of Chinese
Herbal Medicine. With untargeted metabolomics combined
with bioinformatic approaches, the team unveiled potential
mechanisms underlying the therapeutic effect of turmeric
extract in treating nonalcoholic fatty liver diseases (NAFLD).
Highlighted in this special issue also is two meta-
analysis papers on the efficacy and safety of therapies com-
bining Chinese Medicine and conventional treatments as
follows. He and colleagues reported on the clinical effects
of oxymatrine, a compound isolated from Sophorae Flaves-
centis Radix, on lamivudine-induced tyrosine-methionine-
aspartate-aspartate (YMDD) mutation, a common mutation
that causes serious drug resistance in patients with HBV
infection. By recruiting data from 324 clinical studies, the
authors confirmed that YMDD mutation was much lower in
patients receiving both oxymatrine and lamivudine. Another
meta-analysis study focused on the efficacy and safety of
a combined therapy of arsenic trioxide and transcatheter
hepatic arterial chemoembolization (TACE) in treating pri-
mary hepatic carcinoma. The study recruited data from 15
randomized controlled trials (RCTs). Comparative analysis
on 530 cases of treatment with 525 control cases revealed
that the combined treatment appeared effective and safe in
general. However, both studies await further clarification by
future large-scale, high-quality clinical trials.
Animal models play important roles in evaluating herbal
medicines for the treatment of liver diseases. Experimental
evaluation of the pharmacological effects of herbal medicines
on liver diseases is often conducted in various animalmodels.
A review by Tan and colleagues comprehensively summa-
rized the animal models of liver diseases treated by herbal
medicines in recent years. The authors concluded that a
great challenge remained to establish a perfect preclinical
evaluation and suggested that several models in combina-
tion may be better in achieving clinical-relevant outcomes.
Furthermore, the authors highlighted the emerging zebrafish
model as a novel approach in evaluating the efficacy of herbal
medicines for liver diseases.
As a feature, bear bile, one of the animal parts from bears,
is an important constituent in liver-protecting prescriptions
in Chinese Medicine, but it incurs controversy due to its
animal origin. The commentary by Li and colleagues iden-
tified several potential herbal substitutes including Coptidis
Rhizoma, which were shown to be able to replace bear bile in
terms of its pharmacological effects as well as clinical efficacy
in treating liver diseases.
In summary, this special issue has collected state-of-the-
art reports on herbal treatment of liver diseases and explored
new heights in hepatology. Although it does not cover all
aspects of progress in this area, we hope that it will be of
interest to researchers in the field of ethnopharmacology and
life sciences, as well as clinical hepatology, and will lay the
foundation for future development.
3. The Road Ahead
About a hundred years ago, Chinese Medicine was the only
medical system in China and it has been merged into the
mainstream medical system nowadays in Mainland China.
It is also one of the officially recognised medical systems in
Taiwan, Macau, and Hong Kong as well as several Asian-
Pacific and European countries. Based on two thousand
years of clinical experiences and over a hundred years of
scientific research, ChineseHerbalMedicine has nowbecome
an important resource for drug discovery as well as a valuable
complementary and alternative medicine worldwide. The
Chinese Medicine-inspired discovery of antimalarial drug
artemisinin by Youyou Tu was honoured by a Lasker Award
in Clinical Medicine in 2011 and a Nobel Prize in Physi-
ology or Medicine in 2015, and this has impelled Chinese
Medicine research. Indeed, discovery of drug candidates for
liver diseases has been inspired by Chinese Medicine too.
For example, based on ethnopharmacological properties of
Chinese Medicine, many studies on bear bile and other
animal bile have identified its chemical profiles, pharma-
cological effects, and mechanisms of action; in particular,
ursodeoxycholic acid (UDCA) isolated from bear bile has
been synthesized and developed to be a drug for treating
(cholesterol) gallstones [1] and its derivatives ursodiol is
the only FDA approved drug to treat primary biliary cir-
rhosis [2]. Looking forward, what more can we do with
Chinese Herbal Medicine?The high-throughput approach in
discovering active compounds from Chinese Medicines for
liver disease treatment remains very attractive, and gaining
further clues and hints through continued exploration of
clinical experiences and traditional wisdoms should also be
appreciated. From2014 to 2015, a supplement series in Science
have been published to illustrate a panorama of the art and
science of Traditional Medicine [3–5]. In one of the Science
supplements, two editors of this special issue, Xu et al. have
critically discussed the hunt for antifibrotics and profibrotics
from botanicals and proposed an efficacy-based strategy for
discovery of botanical antifibrotics [6]. Herein, we propose a
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Figure 1:Three categories of research in Chinese Medicine. In the long term, we hope to establish a research platform on Chinese Medicines
by interdisciplinary technologies and concepts in molecular medicine, omics, informatics, nanotechnology, systems biology, integrative
medicine, individualmedicine, translationalmedicine, evidence-basedmedicine, and so forth.Wepropose a research pyramid platformby the
following three categories: (a) research on new drug discovery from Chinese Medicines, (b) research on evidence-based complementary and
alternative medicine from Chinese Medicine, and (c) research on the science and art of Chinese Medicine and other therapeutic formalities
in Chinese Medicine practice.
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Figure 2: Research strategy proposed for Chinese Herbal Medicines in hepatology: Coptis (huanglian in Chinese) and its single pure
compound and composite formula used as an examples. Using differentmaterials, diseasemodels, and omics data, researchwill be clarified for
bioactivity relevance of the chemical profile, pharmacological network of bioactive-relevant compounds, and interactions amongst multiple
components on molecular targets in this complicated system of Chinese Medicine.
research pyramid (Figure 1), which links traditional practice,
evidence-based medicine to the discovery of new drugs.
Both single pure compound and multiple components
are important for scientific research for Chinese Medicine.
However, apart from purified compounds or individual
herbal extracts, composite formulae are the most commonly
used in the clinical practice of Chinese Medicine. Given their
nature, it is still difficult to produce herb-derived natural
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products with identical quality from laboratory to laboratory
or even batch to batch in the same laboratory, as the different
resources or minor variance in herb growth conditions and
production protocols would largely harm reproducibility.The
key point is to assure stable research materials and follow
good practices (GAP, GMP, GLP, and GCP) to facilitate
reliable and reproducible results. Guidelines of good practice
in handling herbal materials from farm to dispensary may
be available at national level but vary across countries and
region and lack at global level. Some pioneering attempts
have been made since 2009 to develop and disseminate good
practice guidelines on Chinese Medicine research [7, 8].
Further development of such guidelines would heavily rely
on international, intersectoral, and interdisciplinary collabo-
rations.
Another challenge in the current research on traditional
medicine is the uncertainty of mechanisms of action and the
possibility of multiple targets. Containing multiple compo-
nents, herbalmedicinemay act on different targets to regulate
biological responses in cellular, animal, and human sys-
tems. This polypharmacological property of herbal medicine
requires data capturing and mining at multiple layers of
biological responses necessary for systematic understanding
of its action. For this, an omics- and systems biology-based
approach will be needed. Omics are powerful technologies
for exploring characteristics of herbs in its nature of systems
biology. By using systems biology and omics technologies,
omic data can be tracked and understood by using available
online database. Construction of intralayer and interlayer
regulatory network gives rise to multidimensional pictures
connecting the chemical and biological identity of herbal
medicine.
Like any other traditionalmedicines and ethnomedicines,
ChineseMedicine relies on natural resource and some species
(plants or animals) effective for liver disease are endangered.
The medicinal use of these endangered species has raised
ethical and legal concerns. Identification and synthesis of
bioactive components from endangered species and search
for replacement for endangered species should thus be an
essential topic in current and future research.
Of note, three papers in this special issue focused on
the pharmacological properties of berberine, a compound
isolated from a herb commonly used in Chinese Medicine,
including for the treatment of liver diseases. Berberine is an
active natural compound that possesses multiple pharmaco-
logical properties, and the use of berberine and berberine-
containing herbs in treating liver diseases has been system-
ically reported by the Lead Guest Editor’s laboratory [9–
13], including for the treatment of acute [9] and chronic
liver damage [10] and hepatic cancer [11–13]. Thus, berberine
and berberine-containing herbs have the potential to be
developed into novel treatments for liver diseases and these
studies can be a paradigm for study of Chinese Herbal
Medicines in hepatology (Figure 2).
Finally, efficacy, safety, and mechanisms of action remain
obscure for most Chinese Medicines widely used in the
treatment of liver diseases. Upon publication of this special
issue, a new exploration of Chinese Herbal Medicines in
hepatology begins.
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